Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Ongoing Advances Transforming Treatment in Myeloma

April 2nd 2018

Noa Biran, MD, discusses treatment breakthroughs and emerging advances in the field of multiple myeloma.

Dr. Biran Discusses Doublets Versus Triplets in Myeloma

March 30th 2018

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses doublets versus triplets in the treatment of patients with multiple myeloma.

Dr. Landgren on the Use of Triplets Versus Quadruplets in Multiple Myeloma

March 26th 2018

C. Ola Landgren, MD, PhD, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the superiority of 3-drug regimens and the next steps in the treatment of patients with multiple myeloma.

Dr. Lonial Discusses Ongoing Phase III Trials in Multiple Myeloma

March 21st 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses ongoing phase III studies in patients with multiple myeloma.

Dr. Lonial on Differentiating Patients With Smoldering and Multiple Myeloma

March 13th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses differentiating patients with smoldering myeloma and multiple myeloma.

Dr. Wolf Discusses Treatment Options for Multiple Myeloma

March 9th 2018

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with multiple myeloma.

Myeloma Expert Provides Insight on Practice-Changing Data

March 2nd 2018

Jesus Berdeja, MD, provides an update on practice-changing data for the treatment of patients with multiple myeloma.

Dr. Richter on Toxicities of Treatments for Multiple Myeloma

February 28th 2018

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses toxicities in the treatment of patients with multiple myeloma.

Berdeja Looks Ahead in Multiple Myeloma Treatment

February 26th 2018

Jesus Berdeja, MD, reflects on pivotal studies in multiple myeloma and discussed potential advancements in the upcoming year.

Dr. Berdeja Discusses the Future of Treatment for Myeloma

February 24th 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses the future of treatment for patients with myeloma.

Denosumab Approaches European Approval for Myeloma

February 23rd 2018

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.

Autologous Stem Cell Transplantation in Multiple Myeloma

February 20th 2018

Phyllis McKiernan, a nurse practitioner at John Theurer Cancer Center, Hackensack Medical Center, discusses the outcomes of a study investigating autologous stem cell transplantation (ASCT) in elderly patients with multiple myeloma.

Pomalidomide Effective in Multiple Myeloma With Renal Impairment

February 20th 2018

Pomalidomide in combination with low-dose dexamethasone induced an overall response rate of up to 39% in patients with relapsed/refractory multiple myeloma with renal impairment.

Pivotal Denosumab Data Published Highlighting Efficacy in Myeloma

February 14th 2018

Denosumab was noninferior to zoledronic acid in preventing skeletal-related event in patients with newly diagnosed multiple myeloma.

Dr. Usmani Discusses Molecular Profiling in Myeloma

February 13th 2018

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses molecular profiling in patients with multiple myeloma.

Dr. Shah on Cellular Therapies for Patients With Myeloma

February 12th 2018

Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Comprehensive Cancer Center, discusses the potential of chimeric antigen receptor T-cell therapy in myeloma.

Expert Highlights Early Promise of Selinexor in Myeloma

February 8th 2018

Cristina Gasparetto, MD, discusses selinexor in combination with daratumumab and dexamethasone in patients with relapsed/refractory myeloma.

Higher Distress Scores Linked With Lower Survival in Myeloma

February 8th 2018

John Richter, MD, discusses the findings form the self-reported symptom and psychological survey in patients with multiple myeloma.

Dr. Bustoros on Next-Generation Sequencing in Multiple Myeloma

February 7th 2018

Mark W. Bustoros, MD, Dana-Farber Cancer Institute, discusses the role of next-generation sequencing for patients with multiple myeloma.

Pomalidomide Triplet Improves PFS in Relapsed/Refractory Myeloma

February 7th 2018

Adding pomalidomide to the combination of bortezomib and low-dose dexamethasone led to a significant improvement in progression-free survival in patients with relapsed/refractory myeloma with prior exposure to lenalidomide.